EMP3

Across TCGA pan-cancer cohorts, EMP3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EMP3 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher EMP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMP3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, UCEC, and CCRCC are the cancer types where EMP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.499	0.858	<.001	62	view →
UCEC	DFS	Median	II,III,IV	0.353	1.000	.005	30	view →
CCRCC	DFS	Median	III,IV	0.316	1.000	.004	12	view →
PDAC	DFS	Tertile	All	0.248	0.542	.008	12	view →
GBM	DFS	Tertile	All	0.189	0.344	.022	5	view →
LUAD	DFS	Median	All	0.909	0.891	.028	3	view →
HNSC	DFS	Quartile	II,III,IV	0.584	0.829	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EMP3–LSCC (DFS)

Open the LSCC breakdown →